These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

892 related items for PubMed ID: 31635815

  • 1. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.
    Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E.
    Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815
    [Abstract] [Full Text] [Related]

  • 2. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
    Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR.
    Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Robinson D.
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
    Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stölzel M, Herholdt C, MacDiarmid S, BESIDE study investigators.
    Eur Urol; 2016 Jul; 70(1):136-145. PubMed ID: 26965560
    [Abstract] [Full Text] [Related]

  • 7. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K.
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [Abstract] [Full Text] [Related]

  • 8. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
    Chen HL, Chen TC, Chang HM, Juan YS, Huang WH, Pan HF, Chang YC, Wu CM, Wang YL, Lee HY.
    World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballéa S, Nazir J, Chapple C.
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [Abstract] [Full Text] [Related]

  • 10. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
    Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stölzel M, Choudhury N, Drake MJ.
    Eur Urol Focus; 2017 Dec; 3(6):629-638. PubMed ID: 28916436
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K.
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment.
    Gratzke C, Chapple C, Mueller ER, Robinson D, Rolland C, Staskin D, Stoelzel M, Maanen RV, Siddiqui E.
    Eur Urol; 2019 Dec; 76(6):767-779. PubMed ID: 31416636
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C.
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [Abstract] [Full Text] [Related]

  • 14. Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II).
    Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER.
    Eur Urol; 2018 Oct; 74(4):501-509. PubMed ID: 29866467
    [Abstract] [Full Text] [Related]

  • 15. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [Abstract] [Full Text] [Related]

  • 16. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial.
    Soliman MG, El-Abd S, El-Gamal OM, Raheem AA, Abou-Ramadan AR, El-Abd AS.
    Urol Int; 2021 Feb; 105(11-12):1011-1017. PubMed ID: 34010843
    [Abstract] [Full Text] [Related]

  • 17. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, Uno S, Yamaguchi O.
    Eur Urol Focus; 2020 Jul 15; 6(4):729-737. PubMed ID: 31718957
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
    Drake MJ, MacDiarmid S, Chapple CR, Esen A, Athanasiou S, Cambronero Santos J, Mitcheson D, Herschorn S, Siddiqui E, Huang M, Stoelzel M.
    Int J Clin Pract; 2017 May 15; 71(5):. PubMed ID: 28419650
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence.
    Özkidik M, Coşkun A, Asutay MK, Bahçeci T, Hamidi N.
    Int Braz J Urol; 2019 May 15; 45(4):782-789. PubMed ID: 31136113
    [Abstract] [Full Text] [Related]

  • 20. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P.
    Urology; 2013 Aug 15; 82(2):313-20. PubMed ID: 23769122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.